摘要
IL-4和TNF-α是引人注目的抗肿瘤活性因子,两者在抗肿瘤及免疫调节方面具有协同作用。我们利用逆转录病毒载体Xd1构建了插入IL-2和TNF-α融合基因的重组逆转录病毒载体XdF,融合基因包括编码IL-2前导肽和IL-2和TNF-α成熟肽的序列。重组载体用Lipofectin方法引入病毒包装细胞PA317,挑选G418抗性克隆,用NIH3T3细胞测定病毒滴度,获得一滴度为1×10 ̄4CFU/ml的高滴度克隆。超速离心浓缩这一重组病毒上清,转导人卵巢癌细胞系SKOV3,经G418筛选获得抗性克隆。PCR可从融合基因转导的细胞DNA中扩增出1.1kb的融合基因片断,证明目的基因完整的整合在细胞的基因组DNA中,测其上清中的IL-2和TNF-α活性结果显示:IL-2的活性为8-15U/10 ̄6cells/24h,TNF-α的活性为150-400U/10 ̄6cells/24h。这一结果表明逆转录病毒介导的融合基因可以在卵巢癌细胞中获得有效表达,表达的融合基因产物在体内和体外部对肿瘤细胞的生长具有抑制作用。
oth IL-2 and TNF-α are cytokines with antitumor activity.In order to observe the feasiblity of cytokine fu-sion gene expression in tumor cells,we used retroviral vector Xdl to construct recombinant retroviral vector XdFwith an inserted IL-2 and TNF-αfusion gene.The fusion gene included the sequences encoding the signal peptide ofIL-2 and mature peptide of IL-2 and TNF-α.The plasmid vector was introduced into packaging cell line PA 317 bylipofectin method.The G418-resistant colonies were selected and the supernatants of the colonies were used to de-termine the virus titers with NIH3T3 cells,A higher-titer colony of 1×1O4CFU/ml was obtained.The supernatantwas used to transduced the human ovavian cancer cell line SKOV 3 after being concantrated 100 times by ultracen-trifugation.The G418-resistant colonies of ovavian cancer cells were obtained by G418 screening and PCR was usedto identify the integration of the fusion gene in genomic DNA of G418-resistant human ovavian cancer cell line.Thebiologic activity assay of IL-2 and TNF-αin the superntant demonstrated that the IL-2 and TNF-α activity was inthe range of 8-15U/1O6cells/24h and 150-400U/106cells/24h,respectively.This rcsults showed that the IL-2 andTNF-α fusion gene could be efficiently expressive in the transduced human ovavian cancar cells and the secreting o-varian tumor cells had a much decreased tumorigenicity in mude mice.
出处
《中华微生物学和免疫学杂志》
CSCD
北大核心
1994年第5期309-313,共5页
Chinese Journal of Microbiology and Immunology
关键词
融合基因
基因转移
基因表达
卵巢癌细胞
Fusion gene
Retriviral-mediated gene transfer
Gene expression
Human ovarian tumor cell